GW501516 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Absorption spectroscopy is spectroscopy that involves techniques that measure the absorption of electromagnetic radiation, as a function of frequency or wavelength, due to its interaction with a sample. The sample absorbs energy, i.e., photons, from the radiating field. The intensity of the absorption varies as a function of frequency, and this variation is the absorption spectrum. Absorption spectroscopy is performed across the electromagnetic spectrum. Absorption spectroscopy is employed as an analytical chemistry tool to determine the presence of a particular substance in a sample and, in many cases, to quantify the amount of the substance present. Infrared and ultraviolet–visible spectroscopy are particularly common in analytical applications. Absorption spectroscopy is also employed in studies of molecular and atomic physics, astronomical spectroscopy and remote sensing. There is a wide range of experimental approaches for measuring absorption spectra. The most common arrangement is to direct a generated beam of radiation at a sample and detect the intensity of the radiation that passes through it. The transmitted energy can be used to calculate the absorption. The source, sample arrangement and detection technique vary significantly depending on the frequency range and the purpose of the experiment. Following are the major types of absorption spectroscopy:
It is expected that improvement of experimental sensitivity will allow discovery of very mild radioactivity of some isotopes now considered stable. For example, in 2003 it was reported that bismuth-209 (the only primordial isotope of bismuth) is very mildly radioactive, with half-life (1.9 ± 0.2) × 1019 yr, confirming earlier theoretical predictions from nuclear physics that bismuth-209 would very slowly alpha decay. Isotopes that are theoretically believed to be unstable but have not been observed to decay are termed observationally stable. Currently there are 105 "stable" isotopes which are theoretically unstable, 40 of which have been observed in detail with no sign of decay, the lightest in any case being 36Ar. Many "stable" nuclides are metastable but have not been observed to decay, and are expected to undergo very rare kinds of radioactive decay, including double beta decay. 146 nuclides from 62 elements with atomic numbers from 1 (hydrogen) to 66 (dysprosium) except 43 (technetium), 61 (promethium), 62 (samarium), and 63 (europium) are theoretically stable to any kind of nuclear decay — except for the theoretical possibility of proton decay, which has never been observed despite extensive searches for it; and spontaneous fission (SF), which is theoretically possible for the nuclides with atomic mass numbers ≥ 93, that is all those with atomic numbers ≥ 41. Besides SF, other theoretical decay routes for heavier elements include:
2 LiCoO2 (s) + 3 H2SO4 + H2O2 → 2 CoSO4 (aq) + Li2SO4 + 4 H2O + O2 Once leached, the metals can be extracted through precipitation reactions controlled by changing the pH level of the solution. Cobalt, the most expensive metal, can then be recovered in the form of sulfate, oxalate, hydroxide, or carbonate. Recycling methods experiment with the direct reproduction of the cathode from the leached metals. In these procedures, concentrations of the various leached metals are premeasured to match the target cathode and then the cathodes are directly synthesized. The main issues with this method, however, are the large volume of solvent required and the high cost of neutralization. Although it is easy to shred up the battery, mixing the cathode and anode at the beginning complicates the process, so they will also need to be separated. Unfortunately, the current design of batteries makes the process extremely complex and it is difficult to separate the metals in a closed-loop battery system. Shredding and dissolving may occur at different locations.
Sources: en.wikipedia.org
=== Prize money === In April 2026, FIFA confirmed the prizes for all participating nations. The total distribution of prize money for the expanded tournament was $871 million, nearly double the amount from the 2022 World Cup. Of this total, $671 million was allocated for performance-based prizes, with the remaining $200 million paid out among teams regardless of performance. Each qualified team received preparation money in the amount of $2.5 million; a team that was eliminated in the group stage would receive a minimum total amount $12.5 million at the tournament, with the winner receiving a total of $52.5 million.
=== General === Peter Atkins & Julio de Paula, 2006, "Physical chemistry," 8th Edn., New York, NY, USA:Macmillan, ISBN 0716787598, accessed 21 June 2015. [E.g., see p. 422 for a group theoretical/symmetry description of atomic orbitals contributing to bonding in methane, CH4, and pp. 390f for estimation of π-electron binding energy for 1,3-butadiene by the Hückel method.] Thomas H. Lowry & Kathleen Schueller Richardson, 1987, Mechanism and Theory in Organic Chemistry, 3rd Edn., New York, NY, USA:Harper & Row, ISBN 0060440848, accessed 20 June 2015. [The authoritative textbook on the subject, containing a number of appendices that provide technical details on molecular orbital theory, kinetic isotope effects, transition state theory, and radical chemistry.] Eric V. Anslyn & Dennis A. Dougherty, 2006, Modern Physical Organic Chemistry, Sausalito, Calif.: University Science Books, ISBN 1891389319. [A modernized and streamlined treatment with an emphasis on applications and cross-disciplinary connections.] Michael B. Smith & Jerry March, 2007, "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure," 6th Ed., New York, NY, USA:Wiley & Sons, ISBN 0470084944, accessed 19 June 2015. Francis A. Carey & Richard J. Sundberg, 2006, "Advanced Organic Chemistry: Part A: Structure and Mechanisms," 4th Edn., New York, NY, USA:Springer Science & Business Media, ISBN 0306468565, accessed 19 June 2015. Hammett, Louis P. (1940) Physical Organic Chemistry, New York, NY, USA: McGraw Hill, accessed 20 June 2015.
Cyproheptadine, sold under the brand name Periactin among others, is a first-generation antihistamine which is used to treat allergies. In addition, it has a number of off-label uses, such as treatment of serotonin syndrome, insomnia, and use as an appetite stimulant. The drug is taken orally. It is an antihistamine and hence acts as a histamine H1 receptor antagonist. In addition to its antihistamine activity, cyproheptadine has anticholinergic, antiserotonergic, antidopaminergic, and local anesthetic properties. These activities make cyproheptadine useful for various additional uses besides antihistamine indications. As a first-generation antihistamine, cyproheptadine crosses the blood–brain barrier and can produce sedation. The drug can also produce significant central anticholinergic effects at clinically used doses. Cyproheptadine was patented in 1959 and came into medical use in 1961. In 2023, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Sources: en.wikipedia.org
=== Drugs === Chlorphenamine, a first-generation alkylamine antihistamine Creatine phosphate, a chemical used to store phosphates in the body Cyclophosphamide, a medication to suppress the immune system
In February 1968, ruling on Madzimbamuto's appeal, Beadle concluded that the Smith administration would be recognised by the local judiciary as the de facto government by virtue of its "effective control over the state's territory", but that de jure recognition would be withheld as this was not "firmly established". Madzimbamuto applied for the right to appeal to the British Privy Council; the Rhodesian Appellate Division promptly ruled that he had no right to do so, but the Privy Council considered his case anyway. In late February 1968, considering the fate of James Dhlamini, Victor Mlambo and Duly Shadreck, three black Rhodesians convicted of murder and terrorist offences before UDI, Beadle ruled that Salisbury retained its pre-UDI powers regarding executions and could carry out death sentences. Whitehall announced on 1 March that at the request of the UK government, the Queen had exercised the royal prerogative of mercy and commuted the three death sentences to life imprisonment. Dhlamini and the others applied for a permanent stay of execution on this basis. At the hearing for Dhlamini and Mlambo on 4 March 1968, Beadle argued that he saw the statement from London as a decision by the UK government and not the Queen herself, and that in any case the 1961 constitution had transferred the prerogative of mercy from Britain to the Rhodesian Executive Council. "The present government is the fully de facto government and as such is the only power that can exercise the prerogative", he concluded.
3 hours, allowing enough time for base excision repair mechanisms to correct the change. However, 4-OHE2-1-N3Ade exhibits instantaneous depurination, leading to error-prone repair and the induction of mutations. Indeed, E2-3,4-Q has been shown to cause A-to-G mutations in the gene coding for H¬-ras, ras being vital to the correct regulation of the cellular response to growth factors. Though 2- and 4-OHE2 have similar redox potentials and thus similar redox cycling activity, the greater carcinogenic capacity of 4-OHE2 can be attributed to its increased reactivity with DNA. Another harmful effect of estrogen redox cycling is the production of superoxide and hydroxyl radicals. P450 reductase catalysis produces superoxide radicals, which can, in the presence of superoxide dismutase and Fe3+, form highly reactive hydroxyl radicals capable of damaging virtually all macromolecules.
=== Stem cells === There is a bioengineering technique that uses stem cells to create corneas or part of corneas that can be transplanted into the eyes. Corneal stem cells are removed from a healthy cornea. They are collected and, through laboratory procedures, made into five to ten layers of cells that can be stitched into a patient's eye. The stem cells are placed into the area where the damaged cornea tissue has been removed. This is a good alternative for those that cannot gain vision through regular cornea transplants. A new development, announced by the University of Cincinnati Medical School in May 2007, would use bone marrow stem cells to regrow the cornea and its cells. This technique, which proved successful in mouse trials, would be of use to those with inherited genetic degenerative conditions of the cornea, especially if other means like a transplant are not feasible. It works better than a transplant because these stem cells keep their ability to differentiate and replicate, and so keep the disease from recurring, longer and better.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.